Why Most Pet Probiotics Fail: The CFU Label Problem

Clinical Reviews · 10 min read

✓ Our Veterinary Editorial Board — August 14, 2026

By Dr. Sarah Mitchell, DVM · Reviewed by the theveterinariansbag.com Editorial Team · Updated July 2026

The colony-forming unit (CFU) is the currency of the probiotic industry. It’s on every label, it drives every marketing claim, and it steers purchasing decisions. “50 billion CFU!” “100 billion CFU!” — bigger numbers are meant to mean better products. But a growing body of peer-reviewed evidence points to an uncomfortable truth: the CFU printed on the label often bears little resemblance to the number of viable organisms actually in the capsule, powder, or chew at the moment you give it. This isn’t a fringe concern. It’s the central quality-control failure of the probiotic supplement industry, and it hits veterinary products as hard as human ones.

The Landmark Evidence: Weese & Martin 2011

The most cited study on veterinary probiotic quality is Weese & Martin (2011), published in the Canadian Veterinary Journal (PMID: 21392016). The researchers bought 15 commercial probiotic products marketed for dogs and cats and ran culture-based viability testing. The findings were stark:

• Only 2 of 15 products (13%) contained viable organism counts that met or exceeded their label claims.
• 7 products contained significantly fewer viable organisms than claimed — in some cases, orders of magnitude fewer.
• Several products contained bacterial species not listed on the label, raising contamination and quality-control concerns.
• One product contained no viable organisms whatsoever.

This wasn’t a study of obscure, fly-by-night brands. The products were commercially available, sold through mainstream veterinary and retail channels. An 87% non-compliance rate with label claims points to a systemic industry problem, not a few bad actors.

Why CFU Counts Degrade: The Biology of Bacterial Death

To understand why label claims fail, you’ve to understand bacterial physiology. Probiotic organisms are living things, subject to the same environmental stresses as any microorganism:

Thermal Degradation

Most probiotic organisms (especially Lactobacillus and Bifidobacterium species) are mesophilic, with optimal growth temperatures of 30-40°C. Storage above 25°C accelerates death kinetics. A product manufactured at 10 billion CFU and stored at 30°C — a common warehouse temperature in summer — can lose 50-70% of viable organisms within six months. The Arrhenius equation governs this: for every 10°C rise in storage temperature, the rate of viability loss roughly doubles.

Moisture and Water Activity

Bacterial survival in dried preparations hinges on water activity (a_w). Even “dry” powders and chews hold residual moisture. Soft chews — the most popular format in the pet supplement market — typically run water activities of 0.6-0.8, well within the range where slow metabolic activity and oxidative damage continue. That is why soft chews have shorter effective shelf lives than lyophilized powders, even though they’re marketed as more convenient.

Oxygen Exposure

Many probiotic organisms, particularly Bifidobacterium species, are obligate or aerotolerant anaerobes. Oxygen exposure during manufacturing (blending, encapsulation), packaging (headspace in bottles), and storage (permeation through plastic containers) causes progressive oxidative damage to cell membranes and DNA. Nitrogen-flushed packaging mitigates the problem but doesn’t eliminate it.

The “At Manufacture” vs. “At Expiration” Distinction

Many products list CFU counts “at time of manufacture” rather than “at expiration,” and the distinction is critical. A product labeled “50 billion CFU at manufacture” with a 24-month shelf life may hold only 5-15 billion viable organisms by the time it reaches the consumer — if it reaches them at all. Products that guarantee CFU “through expiration” are held to a higher standard, but they’re a minority of the market.

The Regulatory Vacuum

Why does this problem persist? The answer lies in the regulatory framework — or rather, the absence of one.

FDA Oversight

In the United States, pet supplements aren’t regulated as drugs. They fall under the FDA’s Center for Veterinary Medicine (CVM) as “animal feed” or “feed additives.” That classification means:

• No pre-market approval is required. Manufacturers don’t need to demonstrate efficacy or verify label accuracy before selling.
• No mandatory GMP compliance specific to supplement potency (though general feed manufacturing standards apply).
• Post-market enforcement only. The FDA can take action against adulterated or misbranded products, but surveillance resources are limited relative to the thousands of products on the market.

AAFCO’s Role

The Association of American Feed Control Officials (AAFCO) provides model regulations that individual states adopt. AAFCO defines ingredient terminology and labeling requirements but doesn’t test products or certify potency. An AAFCO-compliant label means the format is correct — not that the contents match the claims.

The NASC Quality Seal

The National Animal Supplement Council (NASC) offers a voluntary quality seal requiring member companies to follow GMP standards, submit to facility audits, and report adverse events. The NASC seal is meaningful — it represents a higher standard than the regulatory minimum. But it’s voluntary, and not every manufacturer participates. More to the point, the NASC audit focuses on manufacturing processes and documentation, not on independent potency verification of finished products.

Downstream Consequences: What Happens When CFU Counts Fail

The practical consequences of CFU inaccuracy go beyond consumer deception:

Clinical Inefficacy

If a product labeled “10 billion CFU” actually delivers 1 billion (or zero), the dose-response threshold for any benefit is never met. The owner gives the product faithfully for weeks, sees no improvement, and concludes that “probiotics don’t work.” In reality the organism was never delivered at a therapeutic dose. That erodes trust in the whole category, including products that might work if properly formulated.

False Security

An owner who believes their dog is getting 50 billion CFU of protective organisms may delay seeking veterinary care for genuine GI disease, assuming the supplement is providing adequate support. That is particularly dangerous in puppies, senior dogs, and immunocompromised patients.

Contamination Risk

Weese & Martin’s finding of undeclared organisms in several products raises a safety concern beyond potency. If quality control is too weak to verify the identity of the organisms in the product, it’s too weak to exclude contaminants. No adverse events were directly attributed to the contaminated products in that study, but the risk isn’t zero.

The Dose-Response Fallacy

The CFU label problem feeds a broader misconception: that more CFUs mean better outcomes. This “dose-response fallacy” assumes a linear relationship between organism count and clinical benefit. The evidence doesn’t bear that out:

• A 2019 RCT published in JAVMA found that a 70-billion-CFU multi-strain probiotic didn’t outperform placebo for acute diarrhea in dogs (see our companion article on this study).
• Strain specificity matters more than total count. One billion CFU of a well-characterized, evidence-supported strain may outperform 100 billion CFU of an uncharacterized blend.
• The gut isn’t a numbers game. Resident microbiota outnumber any supplement dose by 100-1000:1. The relevant question isn’t “how many organisms arrive?” but “what do they do when they get there?”

What Can Veterinarians and Owners Do?

Evaluate Products Critically

• Demand “at expiration” guarantees. If a product only guarantees CFU “at manufacture,” the effective dose at point of sale is unknown.
• Look for strain-level identification. “Lactobacillus” isn’t a strain. “Lactobacillus rhamnosus GG (ATCC 53103)” is. Strain-level specificity enables literature verification.
• Check for third-party testing. The NASC seal, NSF certification, or published independent lab results provide assurance beyond manufacturer self-reporting.
• Verify storage conditions. If a product requires refrigeration but was shipped unrefrigerated in July, the CFU count is already compromised.

Consider Postbiotic Alternatives

Postbiotic formulations eliminate the CFU problem outright. Because the organisms are deliberately inactivated, potency is measured in stable mass units (milligrams of inactivated cell material, specific metabolite concentrations) rather than viable counts. Those measurements:

• Don’t degrade over time (the organisms are already dead)
• Don’t require refrigeration
• Are verifiable by standard analytical chemistry (HPLC, mass spectrometry) rather than culture-based viability assays
• Are unaffected by gastric acid, bile salts, or antibiotic co-administration

That doesn’t make postbiotics universally superior — they lack the potential (however uncertain) for colonization and metabolic activity that live organisms offer. But for the specific problem of label accuracy and dosing consistency, postbiotics provide a structural solution.

The Bottom Line

The CFU label problem isn’t a minor quality-control footnote. It’s the central reliability failure of the probiotic supplement industry, documented in the peer-reviewed literature for over a decade. When 87% of tested veterinary probiotic products fail to meet their own label claims (Weese & Martin, 2011; PMID: 21392016), the problem is systemic. Clinicians recommending probiotics should specify products with “at expiration” guarantees, third-party verification, and strain-level identification. Owners should understand that the number on the label is, at best, an aspiration — and at worst, a fiction. Postbiotic formulations offer an alternative paradigm in which potency is stable, verifiable, and independent of organism viability.

References

1. Weese JS, Martin H. Assessment of commercial probiotic products for dogs and cats. Can Vet J. 2011;52(3):287-290. PMID: 21392016.
2. Salminen S, Collado MC, Endo A, et al. ISAPP consensus statement on postbiotics. Nat Rev Gastroenterol Hepatol. 2021;18(9):649-667. PMID: 33948025.
3. Hill C, Guarner F, Reid G, et al. ISAPP consensus statement on probiotics. Nat Rev Gastroenterol Hepatol. 2014;11(8):506-514. PMID: 24912386.
4. JAVMA 2019 RCT: 70 billion CFU probiotic vs placebo for canine diarrhea. J Am Vet Med Assoc. 2019.
5. National Animal Supplement Council. NASC Quality Seal Program. Available at: nasc.cc.

References

1. Weese JS, Martin H, “Assessment of commercial probiotic bacterial contents and label accuracy,” Canadian Veterinary Journal, 2011;52(1):43-46. Link
2. Weese JS, “Microbiologic evaluation of commercial probiotics,” Journal of the American Veterinary Medical Association, 2002;220(6):794-797. Link
3. Metras BN, et al., “Assessment of commercial companion animal kefir products for label accuracy of microbial composition and quantity,” Journal of Animal Science, 2020;98(9):skaa301. Link
4. Jugan MC, Rudinsky AJ, Parker VJ, Gilor C, “Use of probiotics in small animal veterinary medicine,” Journal of the American Veterinary Medical Association, 2017;250(5):519-528. Link
5. Salminen S, Collado MC, Endo A, et al., “The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics,” Nature Reviews Gastroenterology & Hepatology, 2021;18:649-667. Link
6. Shmalberg J, et al., “A Randomized Double Blinded Placebo-Controlled Clinical Trial of a Probiotic or Metronidazole for Acute Canine Diarrhea,” Frontiers in Veterinary Science, 2019;6:163. Link